HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice reassessment osimertinib (Tagrisso®)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Avelumab in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of oral semaglutide (Rybelsus®)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum (package advice)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trientine tetrahydrochloride (Cuprior®) [for] the treatment of Wilson's disease
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Bevespi® aerosphere 7.2 micrograms / 5 micrograms
2020	Scottish Health Technologies Group (SHTG)	HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Hyperbaric oxygenotherapy for fybromialga, peripheral vascular disease, neurological disease and other indications]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Effectiveness and safety of endovascular treatment with venous adhesive in varicose veins of the lower extremities]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Analysis of the efficacy and safety of robotic spinal surgery]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea]
2020	Scottish Health Technologies Group (SHTG)	The Scottish asynchronous digital dermatology appointment service (DDAS)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with hormonal therapy as a first-line treatment for HR+ and HER2- metastatic breast cancer
2020	Malaysian Health Technology Assessment (MaHTAS)	Refurbished medical device
2020	Malaysian Health Technology Assessment (MaHTAS)	Resuscitative endovascular balloon occlusion of the aorta (REBOA)
2020	Malaysian Health Technology Assessment (MaHTAS)	Transbronchial cryobiopsy for lung biopsy in interstitial lung disease
2020	Malaysian Health Technology Assessment (MaHTAS)	Hepatitis C virus screening and surveillance tests for dialysis patients
2020	Malaysian Health Technology Assessment (MaHTAS)	Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) for elderly
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mogamulizumab (Mycosis Fungoides, Sézary Syndrome)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (Diffuse Large B-Cell Lymphoma, Combination with Bendamustine and Rituximab)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ponatinib (Reassessment after the Deadline: Chronic Myeloid Leukaemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ponatinib (Reassessment after the Deadline: Acute Lymphoblastic Leukaemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (Reassessment after Expiry: B-cell Acute Lymphoblastic Leukaemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after expiry: diffuse large B-cell lymphoma)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Volanesorsen]
2020	Malaysian Health Technology Assessment (MaHTAS)	Pulsed electromagnetic field therapy – an update
2020	Malaysian Health Technology Assessment (MaHTAS)	Repetitive transcranial magnetic stimulation (rTMS) for patients with stroke
2020	Canadian Agency for Drugs and Technologies in Health (CADTH)	Condition-level review on tuberculosis: repository of evidence and resources
2020	Malaysian Health Technology Assessment (MaHTAS)	Acupuncture for headache, refractory neuralgia, Bell’s palsy, post-stroke, Guillain barre and transverse myelitis
2020	Malaysian Health Technology Assessment (MaHTAS)	Laser fluorescence to detect tooth decay within the tooth structure
2020	Canary Health Service	[Cost-effectiveness of universal childhood vaccination against hepatitis A (update)]
2020	Canary Health Service	[Liquid biopsy for the detection of ovarian or endometrial cancer in samples taken from the Pap smear: PapSEEK]
2020	Canary Health Service	[Transcranial magnetic stimulation for the treatment of cocaine addiction]
2020	Canary Health Service	[Physical exercise intervention in older hospitalized patients for the prevention of functional and cognitive deterioration during hospital admission]
2020	Canary Health Service	[Safety, clinical effectiveness and cost-effectiveness of interventions for the prevention of delirium in hospital admissions]
2020	Canary Health Service	[Effectiveness, safety and cost-effectiveness of real-time continuous interstitial glucose monitoring systems (CGMS-RT) for Diabetes Mellitus type 1 and 2. Update]
2020	Canary Health Service	[Safety, effectiveness, and cost-effectiveness of integrated continuous subcutaneous insulin infusion systems with continuous glucose monitoring sensor]
2020	Canary Health Service	[Cost-effectiveness analysis of newborn screening for severe combined immunodeficiency]
2020	Canary Health Service	[Radiofrequency ablation for metastatic spinal lesions]
2020	Adelaide Health Technology Assessment (AHTA)	Genetic testing for diagnosis of inheritable cardiac rhythm disorders
2020	Adelaide Health Technology Assessment (AHTA)	Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2020	Andalusian Health Technology Assessment Area (AETSA)	[Tumor field therapy in the treatment of glioblastoma. Update]
2020	Andalusian Health Technology Assessment Area (AETSA)	[Care model for women with endometriosis. Systematic review of clinical practice guidelines]
2020	Scottish Health Technologies Group (SHTG)	The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2020	Scottish Health Technologies Group (SHTG)	Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2020	Agency for Care Effectiveness (ACE)	Acupuncture for adults with low back pain and neck pain
2020	Agency for Care Effectiveness (ACE)	Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2020	Agency for Care Effectiveness (ACE)	Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2020	Agency for Care Effectiveness (ACE)	Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	Agency for Care Effectiveness (ACE)	Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020	Agency for Care Effectiveness (ACE)	Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020	Agency for Care Effectiveness (ACE)	Epoprostenol for treating pulmonary arterial hypertension
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	National Authority for Assessment and Accreditation in Healthcare (INEAS)	Vaccination contre la grippe dans le contexte particulier de la pandémie COVID-19 : intérêt et populations prioritaires
2020	Institute for Clinical and Economic Review (ICER)	Supervised injection facilities and other supervised consumption sites: effectiveness and value
2020	Institute for Clinical and Economic Review (ICER)	Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value
2020	Institute for Clinical and Economic Review (ICER)	Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder
2020	Institute for Clinical and Economic Review (ICER)	Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2020	Institute for Clinical and Economic Review (ICER)	Targeted immune modulators for ulcerative colitis: effectiveness and value
2020	Institute for Clinical and Economic Review (ICER)	Modulator treatments for cystic fibrosis: effectiveness and value
2020	Institute for Clinical and Economic Review (ICER)	Alternative pricing models for remdesivir and other potential treatments for COVID-19
2020	Institute for Clinical and Economic Review (ICER)	Acute treatments for migraine
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patient information on interstitial low-dose-rate brachytherapy for localized prostate cancer - addendum to commission N17-04]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the DMP "type 2 diabetes"]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ropeginterferon alfa-2b (polycythaemia vera) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (NSCLC, combination chemotherapy with nab-paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cannabidiol (Lennox-Gastaut syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Development of scientific concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V - rapid report]